Lexaria Bioscience secretary Carle buys $682 in shares

Published 30/07/2025, 16:32
Lexaria Bioscience secretary Carle buys $682 in shares

On July 29, 2025, Vanessa Carle, Secretary of Lexaria Bioscience Corp (NASDAQ:LEXX), purchased 750 common shares of the company. The shares were bought at $0.91, totaling $682, amid a significant 75% decline in share price over the past year. According to InvestingPro analysis, the stock is currently trading below its Fair Value, suggesting potential upside opportunity.

Following the transaction, Carle directly owns 750 common shares of Lexaria Bioscience Corp.

Carle also holds options to acquire 75,000 common shares of Lexaria Bioscience Corp. These options are exercisable at prices ranging from $1.04 to $3.00, with expiration dates between 2026 and 2030.

In other recent news, Lexaria Bioscience Corp. announced interim results from its Phase 1b GLP-1-H24-4 study in Australia, focusing on the DehydraTECH-semaglutide and DehydraTECH-tirzepatide arms. The company also reported that its DehydraTECH technology can reduce side effects in leading GLP-1 weight loss and diabetes drugs, addressing significant challenges with patient retention due to adverse effects. Lexaria has expanded its international patent portfolio to 50, with new patents including one in Australia for treating epilepsy, which will expire in 2044.

Additionally, Lexaria is advancing its drug delivery technology through a collaboration with a pharmaceutical company, referred to as PharmaCO. This collaboration includes completed pre-clinical studies under a Material Transfer Agreement, with further data expected in Q3 2025. H.C. Wainwright adjusted its price target for Lexaria Bioscience, lowering it to $4.00 from $5.00 while maintaining a Buy rating, following the company’s interim study results. Previously, H.C. Wainwright had also lowered the price target from $7.00 to $5.00 after positive partial results from a human pilot study comparing DehydraTECH-liraglutide to Saxenda. These developments highlight Lexaria’s ongoing efforts to enhance its DehydraTECH technology and expand its market presence.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.